Loading…
Loading…
TBRIF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TBRIF and 80,000+ other tickers.
See exactly how TBRIF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TBRIF and 80,000+ other tickers.
Based in Toronto, Canada, Therma Bright Inc., established in 2001 and formerly known as The Jenex Corporation until its rebranding in 2018, specializes in the creation and commercialization of a diverse portfolio of medical and consumer health devices. Their offerings include rapid diagnostic tests for COVID-19, such as AcuVid, which screens for both antigens and antibodies. The company also provides innovative solutions for pain management and other health concerns, featuring InterceptCS, a system utilizing controlled topical heat to prevent cold sores, and Benepod, a hot and cold contrast…
Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, announces that further to its press release of June 23, 2026, it has now issued an aggregate of 6,613,999 common shares at a deemed price of $0.06 per share to settle aggregate debt of $396,840. All shares issued in relation to these debt settlements are subject to a hold period expiring November 30, 2026, in accordance with applicable securities laws and TSXV Policies.
The Company Announces Shares for Debt Settlements Toronto, Ontario--(Newsfile Corp. - June 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, is pleased to announce continued sales momentum for its Venowave mobile compression device in the United States, highlighted by additional follow-on orders from Horizon Health USA ("Horizon") and from Gen-X Med. Building on the rapid deployment of previous shipments, Horizon Health USA has placed a new order for 100 Venowave units.
Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, is pleased to announce that Horizon Health ("Horizon") has purchased an additional 100 Venowave™ units. This second commercial order follows the rapid deployment and clinical success of the initial 100-unit shipment delivered to Horizon in late March 2026.
Therma Bright Builds on Revenue Progress with Initial 100-Unit Venowave™ Order; Signals Expansion into Cosmetic Wellness Market Toronto, Ontario--(Newsfile Corp. - March 31, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, announces it has secured a strategic commercial order for an initial 100 Venowave™ units from Horizon Health ("Horizon"). This milestone order follows a successful 2025 proof-of-concept phase, during which Therma Bright optimized its delivery and support protocols for the U.S. market.
Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, announces that it has granted incentive stock options to its directors, officers and certain consultants of the Company to purchase up to an aggregate of 2,850,000 common shares of the Company pursuant to its 10% rolling stock option plan. All options are fully vested and are exercisable for a period of 2 years at a price of $0.07 per share.